<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04092101</url>
  </required_header>
  <id_info>
    <org_study_id>CHRMS19-0130</org_study_id>
    <secondary_id>U54DA036114-06</secondary_id>
    <nct_id>NCT04092101</nct_id>
  </id_info>
  <brief_title>Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder</brief_title>
  <official_title>Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prevalence of smoking among individuals with opioid use disorder (OUD) is six-fold that of&#xD;
      the general US adult population. The mortality rate of opioid-dependent smokers is four times&#xD;
      that of opioid-dependent nonsmokers, and their response to smoking cessation interventions is&#xD;
      notoriously poor. A national policy of reducing the nicotine content of cigarettes has the&#xD;
      potential to be an effective method of reducing tobacco use prevalence, dependence, and&#xD;
      related adverse health outcomes. Controlled trials in the general smoker population have&#xD;
      demonstrated that switching smokers to low nicotine content cigarettes results in reductions&#xD;
      in cigarettes per day (CPD), dependence and tobacco toxicant exposure, with few adverse&#xD;
      consequences. The investigators believe that the impact of reduced nicotine standards on use&#xD;
      of combusted cigarettes in this population will be moderated considerably by other tobacco&#xD;
      market conditions including (1) availability of alternative sources of non-combusted&#xD;
      nicotine, and (2) whether these alternatives are available under conditions that optimize&#xD;
      their appeal. The investigators hypothesize the same for other vulnerable populations as&#xD;
      well, but achieving significant reductions in use of combusted cigarettes in smokers with OUD&#xD;
      seems especially unlikely in the absence of readily available and appealing alternative&#xD;
      sources of non-combusted nicotine.&#xD;
&#xD;
      The goal of the proposed trial is to experimentally model whether increased availability and&#xD;
      appeal of an alternative, non-combusted source of nicotine (e-cigarettes) will enhance the&#xD;
      effectiveness of a reduced nicotine standard for cigarettes in smokers with OUD.&#xD;
      Additionally, the investigators will test whether allowing participants to personalize the&#xD;
      favor of the e-liquid alters any moderating effects their availability may have on tobacco&#xD;
      cigarette smoking.&#xD;
&#xD;
      Daily smokers who are receiving methadone or buprenorphine treatment will be recruited at&#xD;
      University of Vermont and Johns Hopkins University.&#xD;
&#xD;
      The investigators will study two research cigarettes referred to here as RC1 and RC2. One of&#xD;
      these cigarettes will be a normal nicotine content cigarette and the other will be a reduced&#xD;
      nicotine content cigarette. Investigators will study two e-cigarette conditions referred to&#xD;
      here as EC1 and EC2. Both e-cigarette conditions will involve the same commercially available&#xD;
      devices and same nicotine-containing e-liquid, but in one condition that e-liquid will be&#xD;
      available only in tobacco flavor while in the other condition that e-liquid will be available&#xD;
      in multiple flavors from which participants can choose based on personal taste preference.&#xD;
      Participants will be assigned to one of the following four study conditions: (1) RC1 only;&#xD;
      (2) RC2 only; (3) RC2 + EC1; (4) RC2 + EC2.&#xD;
&#xD;
      Participants will be asked to use only their assigned study products for 16 weeks. Outcome&#xD;
      measures include total CPD, cigarette demand assessed by behavioral economics-based purchase&#xD;
      tasks, craving, withdrawal, psychiatric symptoms, breath carbon monoxide (CO), biomarkers of&#xD;
      tobacco toxicant exposure, brain function and structure, and airway inflammation (fractional&#xD;
      nitric oxide concentration in exhaled breath [FeNO]).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind dosing of tobacco cigarette nicotine levels.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Cigarettes Smoked Per Day</measure>
    <time_frame>16 weeks</time_frame>
    <description>Cigarettes per day will be assessed for use of cigarettes with different nicotine content.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>RC 1 only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research Cigarettes #1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC 2 only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research Cigarettes #2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC 2 + EC 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research Cigarettes #2 plus E-cigarettes #1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC 2 + EC 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research Cigarettes #2 plus E-cigarettes #2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cigarettes with varying nicotine content</intervention_name>
    <description>1) Altering the nicotine content of the tobacco research cigarette</description>
    <arm_group_label>RC 1 only</arm_group_label>
    <arm_group_label>RC 2 + EC 1</arm_group_label>
    <arm_group_label>RC 2 + EC 2</arm_group_label>
    <arm_group_label>RC 2 only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>E-Cigarettes</intervention_name>
    <description>1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition</description>
    <arm_group_label>RC 2 + EC 1</arm_group_label>
    <arm_group_label>RC 2 + EC 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Maintained on opioid medication&#xD;
&#xD;
          -  21 to 70 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not maintained on opioid medication&#xD;
&#xD;
          -  Under 21 years old&#xD;
&#xD;
          -  Over 70 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacey C. Sigmon, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shirley Plucinski</last_name>
    <phone>9788752361</phone>
    <email>shirley.plucinski@uvm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dustin Lee, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shirley Plucinski</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Plucinski</last_name>
      <phone>978-875-2361</phone>
      <email>shirley.plucinski@uvm.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Stacey C. Sigmon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Biomarkers of Exposure</keyword>
  <keyword>Compensatory Smoking</keyword>
  <keyword>Nicotine Dependence</keyword>
  <keyword>Reduced Nicotine Cigarettes</keyword>
  <keyword>Affective Disorders</keyword>
  <keyword>Tobacco Withdrawal</keyword>
  <keyword>Vulnerable Populations</keyword>
  <keyword>E-Cigarettes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

